RNA assays up sensitivity of urothelial carcinoma detection

August 21, 2012
RNA assays up sensitivity of urothelial carcinoma detection
Cxbladder, a derivative of the RNA assay uRNA, may be an effective alternative to cytology and nuclear matrix protein 22 assays for the detection of urothelial carcinoma, according to a study published in the September issue of The Journal of Urology.

(HealthDay) -- Cxbladder, a derivative of the RNA assay uRNA, may be an effective alternative to cytology and nuclear matrix protein 22 (NMP22) assays for the detection of urothelial carcinoma, according to a study published in the September issue of The Journal of Urology.

To compare the sensitivity and specificity of the RNA tests with cytology and NMP22 assays (NMP22 BladderChek and NMP22 enzyme-linked immunosorbent assay [ELISA]) using cystoscopy as the reference, Paul O'Sullivan, M.D., of Pacific Edge Ltd. in Dunedin, New Zealand, and associates conducted a prospective study of 485 patients presenting with gross hematuria with no history of urothelial cancer.

Of 66 patients with , the researchers found that uRNA detected 62.1 percent of the cases, compared with cytology (56.1 percent), NMP22 ELISA (50 percent), and BladderChek (37.9 percent). Cxbladder detected 82 percent of cases, including 100 percent of tumors stage 1 or greater and 97 percent of high-grade tumors. The specificity of Cxbladder and uRNA were prespecified at 85 percent, and the specificity of , NMP22 ELISA, and BladderChek were 94.5, 88.0, and 96.4 percent, respectively. Cxbladder was able to differentiate between low-grade Ta tumors and other detected urothelial carcinoma with a sensitivity and a specificity of 91 and 90 percent, respectively.

"uRNA and Cxbladder showed improved sensitivity for the detection of urothelial carcinoma compared to the NMP22 assays," the authors write. "Stratification with Cxbladder provides a potential method to prioritize patients for the management of waiting lists."

Several authors disclosed (including employment) to Pacific Edge Ltd., which manufactures Cxbladder.

Explore further: Combination HPV diagnostic test for head and neck cancer outperformed other tests

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Combination HPV diagnostic test for head and neck cancer outperformed other tests

October 3, 2011
Researchers have determined that a combination of P16 immunohistochemistry and DNA qPCR to test for viral E6 can accurately determine the oropharyngeal squamous cell carcinoma, a form of head and neck cancer, which derive ...

PET more sensitive than CT for merkel cell carcinoma

May 15, 2012
(HealthDay) -- Fluorine-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) is significantly more sensitive and equally specific compared with traditional computed tomography (CT) imaging for evaluation of ...

Tests for biomarker may help determine diagnosis of heart attack within hours

December 27, 2011
For patients admitted to an emergency department with chest pain, use of a contemporary or highly sensitive test for levels of troponin I (a protein in muscle tissue) may help rule-out a diagnosis of heart attack, while changes ...

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.